Effects of HER2-binding affibody molecules on intracellular signaling pathways

Tumor Biology

Volumn 27, Issue 4, 2006, Pages 201-210

  Ekerljung, Lina ^a   Steffen, Ann Charlott ^a   Carlsson, Jörgen ^a   Lennartsson, Johan ^b,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody; Akt; Erk; HER2; PLC 1; Signal transduction

Indexed keywords

(Z HER2:4) 2 AFFIBODY; AFFIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 BINDING AFFIBODY; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPASE C GAMMA1; PROTEIN KINASE B; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; Z HER2:342 AFFIBODY;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GENETICS; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; INHIBITION KINETICS; ISOTOPE LABELING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 33646739287     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093023     Document Type: Article

References (28)

1. Schlessinger J, Lemmon MA: SH2 and PTB domains in tyrosine kinase signaling. Sci STKE 2003;2003:RE12.
2. Marmor MD, Skaria KB, Yarden Y: Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 2004;58:903-913.
3. Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-2927.
4. Zhang W, Liu HT: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 2002;12:9-18.
5. Wells A, Grandis JR: Phospholipase C-gamma1 in tumor progression. Clin Exp Metastasis 2003;20:285-290.
6. Thomas SM, Coppelli FM, Wells A, Gooding WE, Song J, Kassis J, Drenning SD, Grandis JR: Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Res 2003;63:5629-5635.
7. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987;237:178-182.
8. Lonardo F, Di Marco E, King CR, Pierce JH, Segatto O, Aaronson SA, Di Fiore PP: The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol 1990;2:992-1003.
9. Chen JS, Lan K, Hung MC: Strategies to target HER2/neu overexpression for cancer therapy. Drug Resist Updat 2003;6:129-136.
10. Park BW, Zhang HT, Wu C, Berezov A, Zhang X, Dua R, Wang Q, Kao G, O'Rourke DM, Greene MI, Murali R: Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol 2000;18:194-198.
11. Albanell J, Codony J, Rovira A, Mellado B, Gascon P: Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003;532:253-268.
12. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26:60-70.
13. Carlsson J, Nordgren H, Sjostrom J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H, Blomqvist C: HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004;90:2344-2348.
14. Steffen AC, Wikman M, Tolmachev V, Adams G, Ståhl S, Carlsson J: In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide based diagnostics. Cancer Biother Radiopharm 2005;20:233-242.
15. Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, Stahl S: Selection and characterization of HER2/neubinding affibody ligands. Protein Eng Des Sel 2004;17:455-462.
16. Lennartsson J, Blume-Jensen P, Hermanson M, Ponten E, Carlberg M, Ronnstrand L: Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene 1999;18:5546-5553.
17. Ronnstrand L, Siegbahn A, Rorsman C, Johnell M, Hansen K, Heldin CH: Overactivation of phospholipase C-gammal renders platelet-derived growth factor beta-receptor-expressing cells independent of the phosphatidylinositol 3-kinase pathway for chemotaxis. J Biol Chem 1999;274:22089-22094.
18. Hagg M, Liljegren A, Carlsson J, Ronnstrand L, Lennartsson J: EGF and dextran-conjugated EGF induces differential phosphorylation of the EGF receptor. Int J Mol Med 2002;10:655-659.
19. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J: Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004;3:1585-1592.
20. Kaufmann SH, Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000;256:42-49.
21. Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC: Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochem Biophys Res Commun 2001;280:274-279.
22. Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T, Patel A, Mills GB, Bast RC Jr: Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 2005;280:2092-2104.
23. Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z: Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2003;2:1113-1120.
24. McPhillips F, Mullen P, Monia BP, Ritchie AA, Dorr FA, Smyth JF, Langdon SP: Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br J Cancer 2001;85:1753-1758.
25. Hansen K, Johnell M, Siegbahn A, Rorsman C, Engstrom U, Wernstedt C, Heldin CH, Ronnstrand L: Mutation of a Src phosphorylation site in the PDGF beta-receptor leads to increased PDGF-stimulated chemotaxis but decreased mitogenesis. EMBO J 1996;15:5299-5313.
26. Ward SG: Do phosphoinositide 3-kinases direct lymphocyte navigation? Trends Immunol 2004;25:67-74.
27. Koizumi N, Hatano E, Nitta T, Tada M, Harada N, Taura K, Ikai I, Shimahara Y: Blocking of PI3K/Akt pathway enhances apoptosis induced by SN-38, an active form of CPT-11, in human hepatoma cells. Int J Oncol 2005;26:1301-1306.
28. Reinhold WC, Kouros-Mehr H, Kohn KW, Maunakea AK, Lababidi S, Roschke A, Stover K, Alexander J, Pantazis P, Miller L, Liu E, Kirsch IR, Urasaki Y, Pommier Y, Weinstein JN: Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res 2003;63:1000-1011.